Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report
-
By
-
Anaya Dewey
-
Joaquina C. Baranda
-
Wei Zhang
-
Mohammad Haeri
-
Brian Milligan
-
Tolga Tuncer
-
May 28, 2026
-
Clinical Scorecard: Case Report of IDH-Wildtype Glioblastoma Featuring a Unique MEF2D-NTRK1 Gene Fusion
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | MEF2D-NTRK1 gene fusion (as per source) |
| Target Population | |
| Care Setting | Oncology and neurosurgery (as per source) |
Key Highlights
- Patient presented with headache, confusion, and unstable gait.
- Histological diagnosis confirmed glioblastoma with unmethylated MGMT promoter.
- Next-generation sequencing revealed a rare MEF2D-NTRK1 gene fusion.
- Treatment included temozolomide, radiotherapy, and tumor treating fields.
Guideline-Based Recommendations
Diagnosis
- Histological confirmation of glioblastoma, IDH-wildtype.
- Molecular profiling to identify gene fusions.
Management
- Concomitant temozolomide and radiotherapy.
- Adjuvant temozolomide with tumor treating fields.
Monitoring & Follow-up
- MRI assessments for radiographic progression.
- Utilization of RANO criteria for evaluation.
Risks
- Potential for pseudoprogression versus true progression.
- Hematological toxicity from treatment regimens.
Patient & Prescribing Data
Adult female with IDH-wildtype glioblastoma.
Combination therapy with repotrectinib and bevacizumab tolerated well.
Clinical Best Practices
Related Resources & Content
